Glaukos Corporation (GKOS) Rating Reiterated by Stephens

Glaukos Corporation (NYSE:GKOS)‘s stock had its “buy” rating reissued by Stephens in a report issued on Friday. They currently have a $47.00 price target on the medical instruments supplier’s stock. Stephens’ price target would indicate a potential upside of 49.68% from the stock’s current price.

A number of other research analysts also recently issued reports on GKOS. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded shares of Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 target price on the stock in a research report on Tuesday, July 4th. Roth Capital cut their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $56.00 target price on shares of Glaukos Corporation in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $49.86.

Shares of Glaukos Corporation (NYSE GKOS) opened at 31.40 on Friday. The company has a 50 day moving average of $37.87 and a 200-day moving average of $41.45. Glaukos Corporation has a 12-month low of $28.72 and a 12-month high of $52.49. The company’s market capitalization is $1.08 billion.

WARNING: This article was published by Equities Focus and is the property of of Equities Focus. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.equitiesfocus.com/2017/09/17/glaukos-corporation-gkos-rating-reiterated-by-stephens.html.

In related news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total value of $3,051,871.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Orbimed Advisors Llc sold 580,200 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 over the last quarter. 16.40% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. Navellier & Associates Inc raised its holdings in Glaukos Corporation by 4.9% during the 2nd quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after buying an additional 1,567 shares during the period. Public Employees Retirement System of Ohio raised its holdings in Glaukos Corporation by 14.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 118,100 shares of the medical instruments supplier’s stock worth $4,898,000 after buying an additional 15,000 shares during the period. Koch Industries Inc. acquired a new stake in Glaukos Corporation during the 2nd quarter worth approximately $683,000. Ameritas Investment Partners Inc. raised its holdings in Glaukos Corporation by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 1,212 shares during the period. Finally, California State Teachers Retirement System raised its holdings in Glaukos Corporation by 54.0% during the 2nd quarter. California State Teachers Retirement System now owns 50,752 shares of the medical instruments supplier’s stock worth $2,105,000 after buying an additional 17,800 shares during the period.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply